Trials / Completed
CompletedNCT03777865
Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India
A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 4, open-label, single-arm, multicenter study in which subjects 6 to 17 years of age will receive 1 dose of 13vPnC.
Detailed description
A Phase 4, open-label, single-arm, multicenter study to describe the safety of 13-valent Pneumococcal Conjugate Vaccine in children 6 to 17 years of age in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 13vPnC | All subjects receive a single dose (0.5mL) of 13vPnC |
Timeline
- Start date
- 2018-12-14
- Primary completion
- 2019-04-17
- Completion
- 2019-04-17
- First posted
- 2018-12-17
- Last updated
- 2020-04-21
- Results posted
- 2020-04-21
Locations
4 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03777865. Inclusion in this directory is not an endorsement.